Company Overview and News

 
Keryx Biopharmaceuticals Announces Late-breaking Ferric Citrate Abstract Accepted for Presentation at the 55th ERA-EDTA Congress

2018-04-19 globenewswire
BOSTON, April 19, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that data from an investigator sponsored trial that evaluated ferric citrate (Auryxia®) use in patients with advanced chronic kidney disease (CKD) will be presented at the 55th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress taking place in Copenhagen from May 24-27, 2018.
Upvote Downvote

2
Zynerba Pharmaceuticals Appoints John P. Butler to Board of Directors

2018-04-16 globenewswire
DEVON, Pa., April 16, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today announced the appointment of John Butler to its board of directors.
Upvote Downvote

 
Keryx Biopharmaceuticals Receives 2018 Corporate Innovator Award from the National Kidney Foundation

2018-04-11 globenewswire
AUSTIN, Texas, April 11, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that the company has received the 2018 Corporate Innovator Award from the National Kidney Foundation. The award will be presented to Keryx today at the NKF Spring Clinical Meetings in Austin, Texas.
Upvote Downvote

1
Keryx Biopharmaceuticals Announces Publication of Data from the Phase 3 Trial of Auryxia® (ferric citrate) for Iron Deficiency Anemia in Patients with Chronic Kidney Disease, Not on Dialysis, in the American Journal of Hematology

2018-04-04 globenewswire
BOSTON, April 04, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced the publication of a post-hoc analysis of Auryxia phase 3 trial data for iron deficiency anemia in adult patients with chronic kidney disease (CKD), not on dialysis, in the online issue of the American Journal of Hematology.
Upvote Downvote

1
KERX / Keryx Biopharmaceuticals, Inc. / BlackRock Inc. - null (Passive Investment)

2018-03-08 sec.gov
us4925151015_030518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) KERYX BIOPHARMACEUTICALS INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 492515101 -------------------------------------------------------- (CUSIP Number) February 28, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of
Upvote Downvote

 
KERX / Keryx Biopharmaceuticals, Inc. / BlackRock Inc. - null (Passive Investment)

2018-03-08 sec.gov
us4925151015_030518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) KERYX BIOPHARMACEUTICALS INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 492515101 -------------------------------------------------------- (CUSIP Number) February 28, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of
Upvote Downvote

 
Options Traders Expect Huge Moves in Keryx (KERX) Stock

2018-03-05 zacks
Investors in Keryx Biopharmaceuticals, Inc. (KERX - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the March 16, 2018 $3.50 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
Upvote Downvote

1
KERX / Keryx Biopharmaceuticals, Inc. 10-K (Annual Report)

2018-02-21 sec.gov
Document Table of Contents UNITED ST
Upvote Downvote

 
KERX / Keryx Biopharmaceuticals, Inc. FORM 8-K (Current Report)

2018-02-17 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 12, 2018     Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)       Delaware   000-30929   13-4087132 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

1
KERX / Keryx Biopharmaceuticals, Inc. / ABRAMS CAPITAL MANAGEMENT, L.P. - 3G/A (Passive Investment)

2018-02-15 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Keryx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities)     492515101   (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed:  [  ]            Rule 13d-1(b)
Upvote Downvote

1
KERX / Keryx Biopharmaceuticals, Inc. / ABRAMS CAPITAL MANAGEMENT, L.P. - 3G/A (Passive Investment)

2018-02-15 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Keryx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities)     492515101   (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed:  [  ]            Rule 13d-1(b)
Upvote Downvote

5
Tracking David Abrams' Abrams Capital Management Portfolio - Q4 2017 Update

2018-02-15 seekingalpha
David Abrams’ 13F portfolio value increased this quarter from $2.56B to $2.97B. The number of positions increased from 18 to 20.
Upvote Downvote

13
Tracking Seth Klarman's Baupost Group Holdings - Q4 2017 Update

2018-02-14 seekingalpha
The portfolio continues to be heavily concentrated, with the top three positions accounting for one-third of the 13F portfolio.
Upvote Downvote

 
Is the Options Market Predicting a Spike in Keryx (KERX) Stock?

2018-02-13 zacks
Investors in Keryx Biopharmaceuticals, Inc. (KERX - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Feb 16, 2018 $3.00 Put had some of the highest implied volatility of all equity options today.
Upvote Downvote

 
KERX / Keryx Biopharmaceuticals, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-09 sec.gov
keryxbiopharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 3 )*       Name of issuer:  Keryx Biopharmaceuticals Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  492515101     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 492515101